Nuritas and Pharmavite LLC have entered into a discovery and option agreement.
Nuritas (Dublin, Ireland) and Pharmavite LLC (West Hills, CA) have entered into a discovery and option agreement. This means that Nuritas will deploy its technology platform that combines artificial intelligence and DNA analysis to predict, unlock, and validate bioactive peptide ingredients, and Pharmavite will formulate these newly discovered bioactive peptides into consumer dosage forms and validate their efficacy through clinical trials.
“As consumer preference and healthcare necessity switches attention from treatment to prevention, nutritional supplements and functional foods play a key role in the Nuritas consumer strategy,” said Neil Foster, head of strategic partnerships for Nuritas, in a press release. “Consumers are increasingly seeking natural products but with the highest possible levels of scientific evidence to support their efficacy.”
Nuritas says it was the first company able to demonstrate how AI can accelerate the discovery of healthcare products, capable of reducing the time from concept to market to less than three years. “Our purpose of bringing the gift of health to life is the foundation for our science-based approach,” said Chioma Ikonte, PhD, director of nutrition sciences at Pharmavite, in a press release. “As a leader in supplemental nutrition, our partnership with Nuritas will enable us to deliver innovative solutions that help people live healthier, more vital lives.”